A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumours With a KRAS G12C Mutation

Official Title

A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumours With a KRAS G12C Mutation

Summary:

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumours with a KRAS G12C mutation.

Trial Description

Primary Outcome:

  • Percentage of Participants With Adverse Events (AEs)
  • Percentage of Participants With Dose-Limiting Toxicities (DLTs)
Secondary Outcome:
  • Plasma Concentrations of GDC-6036
  • Plasma Concentrations of Erlotinib
  • Plasma Concentrations of GDC-1971
  • Serum Concentrations of Atezolizumab
  • Serum Concentrations of Bevacizumab
  • Serum Concentrations of Cetuximab
  • Objective Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST v1.1)
  • Duration of Response (DOR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST v1.1)
  • Progression-free survival (PFS) as determined by the investigator according to Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST v1.1)
  • Relationship Between GDC-6036 Exposure (Maximum Plasma Concentration Observed [Cmax])
  • Relationship Between GDC-6036 Exposure (Time to Maximum Plasma Concentration [Tmax])
  • Relationship Between GDC-6036 Exposure (Half-life [t1/2])
  • Relationship Between GDC-6036 Exposure (Area Under the Curve [AUC])
  • Relationship Between Tumour Pharmacodynamic Effects of GDC-6036

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society